ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
72.83
-0.68 (-0.93%)
Aug 28, 2026, 4:00 PM EDT - Market closed
ANI Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 978.38 | 883.37 | 614.38 | 486.82 | 316.39 | 216.14 | |
Revenue Growth | 30.90% | 43.78% | 26.20% | 53.87% | 46.38% | 3.67% |
Cost of Revenue | 387.4 | 341.31 | 236.61 | 181.51 | 138.79 | 100.61 |
Gross Profit | 590.98 | 542.06 | 377.77 | 305.3 | 177.6 | 115.53 |
Selling, General & Admin | 331.66 | 315.65 | 231.54 | 161.7 | 124.04 | 84.29 |
Research & Development | 49.91 | 51.66 | 44.58 | 34.29 | 22.32 | 11.37 |
Other Operating Expenses | - | - | - | - | - | 0.78 |
Operating Expenses | 467.38 | 458.73 | 343.85 | 255.77 | 203.33 | 143.7 |
Operating Income | 123.6 | 83.33 | 33.92 | 49.53 | -25.73 | -28.17 |
Interest Expense | -30.9 | -32.18 | -33.14 | -35.05 | -28.42 | -11.95 |
Interest & Investment Income | 14.36 | 12.12 | 15.53 | 8.11 | 0.37 | 0.02 |
Currency Exchange Gain (Loss) | -1.12 | 1.93 | - | - | - | - |
Other Non Operating Income (Expenses) | - | - | -4.03 | -0.16 | 0.67 | -4.71 |
EBT Excluding Unusual Items | 105.94 | 65.2 | 12.28 | 22.43 | -53.12 | -44.8 |
Merger & Restructuring Charges | -2.1 | -2.1 | -31.7 | -1.13 | -5.68 | - |
Gain (Loss) on Sale of Investments | 9.91 | 2.82 | 6.31 | - | - | - |
Gain (Loss) on Sale of Assets | -0.38 | -0.38 | 5.35 | - | - | 1.82 |
Asset Writedown | -0.77 | -0.77 | -7.6 | - | -0.11 | -2.37 |
Legal Settlements | 9 | - | - | - | - | -8.75 |
Other Unusual Items | 21 | 31.01 | -6.85 | -1.43 | -3.76 | -1.96 |
Pretax Income | 142.6 | 95.79 | -22.21 | 19.87 | -62.67 | -56.06 |
Income Tax Expense | 34.29 | 17.45 | -3.69 | 1.09 | -14.77 | -13.46 |
Net Income | 108.31 | 78.34 | -18.52 | 18.78 | -47.9 | -42.6 |
Preferred Dividends & Other Adjustments | 8.71 | 8.12 | 1.63 | 3.3 | 1.63 | 0.19 |
Net Income to Common | 99.6 | 70.22 | -20.15 | 15.48 | -49.52 | -42.79 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 21 | 20 | 19 | 18 | 16 | 13 |
Shares Outstanding (Diluted) | 22 | 21 | 19 | 18 | 16 | 13 |
Shares Change | 12.56% | 9.89% | 6.18% | 11.89% | 29.09% | 5.28% |
EPS (Basic) | 4.81 | 3.50 | -1.04 | 0.86 | -3.05 | -3.40 |
EPS (Diluted) | 4.54 | 3.32 | -1.04 | 0.85 | -3.05 | -3.40 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 172.99 | 171.39 | 47.78 | 110.09 | -40.08 | 0.77 |
Free Cash Flow Per Share | 7.85 | 8.07 | 2.47 | 6.05 | -2.46 | 0.06 |
Gross Margin | 60.40% | 61.36% | 61.49% | 62.71% | 56.13% | 53.45% |
Operating Margin | 12.63% | 9.43% | 5.52% | 10.17% | -8.13% | -13.03% |
Profit Margin | 10.18% | 7.95% | -3.28% | 3.18% | -15.65% | -19.80% |
Free Cash Flow Margin | 17.68% | 19.40% | 7.78% | 22.61% | -12.67% | 0.35% |
EBITDA | 209.41 | 174.75 | 101.65 | 109.32 | 33.92 | 19.08 |
EBITDA Margin | 21.40% | 19.78% | 16.55% | 22.46% | 10.72% | 8.83% |
D&A For EBITDA | 85.8 | 91.42 | 67.73 | 59.79 | 59.65 | 47.25 |
EBIT | 123.6 | 83.33 | 33.92 | 49.53 | -25.73 | -28.17 |
EBIT Margin | 12.63% | 9.43% | 5.52% | 10.17% | -8.13% | -13.03% |
Effective Tax Rate | 24.04% | 18.22% | - | 5.50% | - | - |